Decision to list needles and syringes products supplied by B. Braun New Zealand Pty Limited
We are pleased to announce a listing agreement with B. Braun New Zealand Pty Limited (“B. Braun”) for the supply of needles and syringes products to DHBs.
In summary this will result in:
- B. Braun’s needles and syringes products being listed on the Pharmaceutical Schedule from 1 March 2019 under a national agreement that all DHBs may purchase under (“Agreement”).
This is a non-exclusive listing agreement, DHBs would continue to be able to purchase other suppliers’ brands of needles and syringes products.
Any changes to the original proposal?
This decision was subject to a consultation letter dated 12 November 2018.
The listing date has been changed since consultation from 1 February 2019 to 1 March 2019. There were no other significant changes to the agreement following consultation.
Who we think will be most interested
- Suppliers and wholesalers
- All DHB clinical staff including but not limited to:
- Allied Health staff;
- Clinical Engineers;
- Clinical staff working in surgical and medical units, emergency departments, intensive and critical care units, and outpatient units
- District nurses
- Perioperative staff;
- Procurement Officers
- Technical staff.
Detail about this decision
In 2017 PHARMAC issued a Request for Proposals (“RFPs”) for needles and syringes.
The RFP was for non-exclusive national agreements for listing in the Pharmaceutical Schedule.
The list of products will be available on PHARMAC’s website from 1 March 2019, in both a PDF document and an Excel spreadsheet.
DHBs that purchase B. Braun’s needles and syringes must do so under the terms and conditions and at the prices included in the Agreement, from 1 March 2019. DHBs can continue to choose which needles and syringes they purchase.
PHARMAC expects to consult on further agreements with suppliers of needles and syringes over the next few months.
Our response to what you told us
We’re really grateful for the time people took to respond to this consultation.
A summary of the main theme raised in feedback and our response to the feedback received, is set out below.
PHARMAC Staff Comment
Ministry of Health
Advising no technical resource impacts anticipated as a result of proposal